IP Library Granted Patent US 12,569,690
Granted Patent B2
US 12,569,690 · App. 17/770,329 · Granted Mar 10, 2026

Cardiac contractility modulation for atrial arrhythmia patients

Inventors: David Prutchi (Voorhees, NJ); Simeon Ioannis Kedikoglou (Tallahassee, FL); Angela Connolly Stagg (Allendale, NJ); Tamir Ben David (Tel-Aviv, IL)
Assignee: Impulse Dynamics NV
A61N1/36585A61N1/3624A61N1/3628A61N1/36592
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,569,690
App. No.
17/770,329
Granted
Mar 10, 2026
Kind
B2
Abstract

A cardiac treatment device, including: stimulation circuitry configured to generate a non-excitatory electrical signal which, when applied to ventricular tissue during a ventricular refractory period thereof improves a condition of heart failure in human patients; atrial arrhythmia detection circuitry; and decision circuitry which controls the stimulation circuitry to delivery said signal, also when said atrial arrhythmia detection circuitry detects an atrial arrhythmia.

Claims (51)

1 . A cardiac treatment device, comprising:

a stimulation circuitry configured to:

generate a non-excitatory electrical signal, wherein when said signal is configured to be applied to a ventricular tissue during a ventricular refractory period it improves a condition of heart failure in human patients;

an atrial arrhythmia detection circuitry; and

a decision circuitry which controls the stimulation circuitry to deliver said signal during said ventricular refractory period, both when said atrial arrhythmia detection circuitry detects an atrial arrhythmia and when said atrial arrhythmia detection circuitry does not detect said atrial arrhythmia.

2 . A device according to claim 1 , wherein said decision circuitry controls modification of at least one parameter of said signal delivered by said stimulation circuitry in response to a detection of said atrial arrhythmia.

3 . A device according to claim 2 , wherein said modification comprises increasing a spatial range of tissue stimulated by said signal.

4 . A device according to claim 3 , wherein tissue configured to be stimulated by said signal comprises one or more of ventricular septum, right atrium, left atrium, AV node or pulmonary vein's junction with left atria.

5 . A device according to claim 1 , wherein said decision circuitry is configured to avoid said delivery if a ventricular arrhythmia is detected.

6 . A device according to claim 1 , wherein said decision circuitry is configured to allow said delivery if a supra-ventricular arrhythmia is detected.

7 . A device according to claim 1 , wherein said device includes a memory with an indication of a dosage of said signal to be applied and a time duration of application and wherein said decision circuitry is configured to modify an actual duration of signal application according to an actual delivery of signals.

8 . A device according to claim 1 , wherein said device is configured to apply said signal also during a non-refractory time in an atria of said patient.

9 . A device according to claim 1 , wherein said device has no atrial leads.

10 . A device according to claim 1 , wherein said device includes pacing circuitry and wherein said decision circuitry is programmable to selectively prefer applying a non-excitatory signal over applying an increase in pacing in cases of increased cardiac demand.

11 . A device according to claim 1 , wherein said atrial arrhythmia detection circuitry detects atrial arrhythmia from signals measured by one or more ventricular leads.

12 . A device according to claim 1 , wherein said device has no ventricular stimulation leads.

13 . The cardiac treatment device of claim 1 , wherein said non-excitatory electrical signal is configured to be delivered using different parameters when said atrial arrhythmia detection circuitry detects said atrial arrhythmia as compared to when said atrial arrhythmia detection circuitry does not detect said atrial arrhythmia.

14 . A cardiac treatment device, comprising:

a stimulation circuitry configured to:

generate a non-excitatory electrical signal, wherein when said signal is configured to be applied to a ventricular tissue during a ventricular refractory period it improves a condition of heart failure in human patients;

an atrial arrhythmia detection circuitry; and

a decision circuitry which controls the stimulation circuitry to deliver said signal during said ventricular refractory period regardless of detection of presence or absence of said atrial arrhythmia by said atrial arrhythmia detection circuitry.

15 . A cardiac treatment device, comprising:

a stimulation circuitry configured to:

generate a non-excitatory electrical signal, wherein when said signal is configured to be applied to a ventricular tissue during a ventricular refractory period it improves a condition of heart failure in human patients;

an atrial arrhythmia detection circuitry;

a memory with a treatment protocol to deliver said non-excitatory electrical signal according to a schedule, and

a decision circuitry which controls the stimulation circuitry to deliver said treatment during said ventricular refractory period, both when said atrial arrhythmia detection circuitry detects an atrial arrhythmia and when said atrial arrythmia detection circuitry does not detect said atrial arrhythmia.

16 . A method of planning treatment for a patient, comprising:

(a) identifying that a patient has an atrial arrhythmia or a risk to develop thereof; and

(b) planning and implementing a treatment schedule for the patient with an implanted device that generates a non-excitatory electrical signal which, when applied to ventricular tissue during a ventricular refractory period thereof improves a condition of heart failure in human patients, wherein said non-excitatory electrical signal is applied both during an atrial arrhythmia event and in the absence of said atrial arrhythmia event.

17 . A method according to claim 16 , wherein said non-excitatory electrical signal is applied during said atrial arrhythmia event with different parameters than when applied in the absence of said atrial arrhythmia event.

18 . A method according to claim 16 , comprising selecting said patient and performing said planning with a goal of improving a symptom of said atrial arrhythmia by said treating.

19 . A method according to claim 16 , wherein said improving comprises preventing abnormal ventricular activation by said atrial arrhythmia.

20 . A method according to claim 16 , wherein said improving comprising reducing said atrial arrhythmia.

21 . A method according to claim 16 , wherein said planning comprises planning to apply said non-excitatory signal within 20 mm from a ventricular septum.

22 . A method according to claim 16 , wherein said planning comprises planning to apply said non-excitatory signal within an atrium of the heart.

23 . A method according to claim 16 , wherein said planning comprises selecting a power level and an application location to stimulate cardiac tissue in both an atria and a ventricle.

24 . A method according to claim 16 , wherein said identifying comprises selecting for treatment patients with episodic AF or patients with chronic AF.

25 . A method according to claim 24 , wherein said identifying comprises selecting for treatment patients at risk of developing an AA, above 20% in the next year.

26 . A method according to claim 24 , wherein said identifying comprises selecting for treatment patients where at least 50% of beats are treatable using said device when considering safety of the patient.

27 . A method according to claim 16 , wherein said planning comprises planning with a goal to reduce AF episodes in said patient.

28 . A method according to claim 16 , wherein said planning comprises programming the device to apply said signal during a portion of the ventricular refractory period late enough so that said refractory period is extended.

29 . A method according to claim 16 , wherein said planning comprises setting up device parameters to apply said signal to above 20,000 treated beats per day, on the average for a month.

30 . The method of claim 16 , wherein said non-excitatory electrical signal is delivered using different parameters when applied during the atrial arrhythmia event as compared to when applied in the absence of said atrial arrhythmia event.

31 . A method of planning treatment for a patient, comprising:

(a) identifying that a patient has an atrial arrhythmia or a risk to develop thereof; and

(b) planning and implementing a treatment schedule for the patient with an implanted device that generates a non-excitatory electrical signal which, when applied to ventricular tissue during a ventricular refractory period thereof improves a condition of heart failure in human patients, wherein said non-excitatory electrical signal is applied regardless of detection of presence or absence of an event of said atrial arrhythmia.

32 . A method of planning treatment for a patient, comprising:

(a) identifying that a patient has an atrial arrhythmia or a risk to develop thereof; and

(b) planning and implementing a treatment schedule for the patient with an implanted device that generates a non-excitatory electrical signal which, when applied to ventricular tissue during a ventricular refractory period thereof improves a condition of heart failure in human patients, wherein said treatment schedule is a prophylactic treatment according to a schedule, wherein said non-excitatory electrical signal is applied according to said prophylactic treatment schedule, wherein the non-excitatory electrical signal is applied both during an atrial arrhythmia event and in the absence of said atrial arrhythmia event.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Oct 7, 2024
From: KENNEDY LEWIS INVESTMENT MANAGEMENT LLC
To: IMPULSE DYNAMICS N.V.
Reel/Frame 069118/0961 →
SECURITY INTEREST Recorded May 23, 2024
From: IMPULSE DYNAMICS, N.V.
To: PERCEPTIVE CREDIT HOLDINGS IV, LP
Reel/Frame 067526/0072 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2022
From: PRUTCHI, DAVID; KEDIKOGLOU, SIMEON IOANNIS; CONNOLLY STAGG, ANGELA; BEN DAVID, TAMIR
To: IMPULSE DYNAMICS NV
Reel/Frame 060543/0459 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded May 19, 2022
From: IMPULSE DYNAMICS N.V.
To: KENNEDY LEWIS INVESTMENT MANAGEMENT LLC, AS COLLATERAL AGENT
Reel/Frame 060120/0055 →
Continuity (5)
Provisional Application 62924776 · Oct 23, 2019
Provisional Application 62924782 · Oct 23, 2019
Provisional Application 63001343 · Mar 29, 2020
Provisional Application 63042061 · Jun 22, 2020
Related Publication 20220387795A1 · Dec 8, 2022
References Cited (135)
US 4554922A · Prystowsky et al. · 1985 [cited by applicant]
US 5372607A · Stone et al. · 1994 [cited by applicant]
US 6233487B1 · Mika et al. · 2001 [cited by applicant]
US 6263242B1 · Mika et al. · 2001 [cited by applicant]
US 6370430B1 · Mika et al. · 2002 [cited by applicant]
US 6480737B1 · Policker et al. · 2002 [cited by applicant]
US 6597952B1 · Mika et al. · 2003 [cited by applicant]
US 6725093B1 · Ben-Haim et al. · 2004 [cited by applicant]
US 6993385B1 · Routh et al. · 2006 [cited by applicant]
US 7027863B1 · Prutchi et al. · 2006 [cited by applicant]
US 7519426B1 · Koh et al. · 2009 [cited by applicant]
US 7634310B2 · Lee et al. · 2009 [cited by applicant]
US 7953481B1 · Shemer et al. · 2011 [cited by applicant]
US 7991469B2 · Schwartz et al. · 2011 [cited by applicant]
US 8634910B2 · Stahmann · 2014 [cited by applicant]
US 8977353B2 · Rousso et al. · 2015 [cited by applicant]
US 9713723B2 · Shemer et al. · 2017 [cited by applicant]
US 10207110B1 · Gelfand et al. · 2019 [cited by applicant]
US 20030036777A1 · Sheth et al. · 2003 [cited by applicant]
US 20040127804A1 · Hatlesad et al. · 2004 [cited by applicant]
US 20050039745A1 · Stahmann et al. · 2005 [cited by applicant]
US 20050085867A1 · Tehrani et al. · 2005 [cited by applicant]
US 20050090871A1 · Cho et al. · 2005 [cited by applicant]
US 20060100668A1 · Ben-David et al. · 2006 [cited by applicant]
US 20060224190A1 · Gill et al. · 2006 [cited by applicant]
US 20070060962A1 · Pappone · 2007 [cited by examiner]
US 20080021336A1 · Dobak, III · 2008 [cited by applicant]
US 20080103532A1 · Armstrong · 2008 [cited by examiner]
US 20080114411A1 · Lian et al. · 2008 [cited by applicant]
US 20080275520A1 · Hopper et al. · 2008 [cited by applicant]
US 20090030471A1 · Rousso et al. · 2009 [cited by applicant]
US 20090062882A1 · Zhang et al. · 2009 [cited by applicant]
US 20090248101A1 · Anker · 2009 [cited by applicant]
US 20090287103A1 · Pillai · 2009 [cited by applicant]
US 20100069977A1 · Stahmann · 2010 [cited by applicant]
US 20100069985A1 · Stahmann · 2010 [cited by examiner]
US 20100087892A1 · Stubbs et al. · 2010 [cited by applicant]
US 20100248288A1 · Iless et al. · 2010 [cited by applicant]
US 20100305647A1 · McCabe et al. · 2010 [cited by applicant]
US 20110152956A1 · Hincapie-Ordonez et al. · 2011 [cited by applicant]
US 20130006319A1 · Doerr · 2013 [cited by examiner]
US 20130138006A1 · Bornzin · 2013 [cited by examiner]
US 20130218222A1 · Doerr · 2013 [cited by applicant]
US 20160045732A1 · Grenz et al. · 2016 [cited by applicant]
US 20170245794A1 · Sharma et al. · 2017 [cited by applicant]
US 20170348524A1 · Matos · 2017 [cited by applicant]
US 20180214698A1 · Cuchiara · 2018 [cited by applicant]
US 20190060632A1 · Asirvatham et al. · 2019 [cited by applicant]
US 20190329043A1 · Sharma · 2019 [cited by applicant]
US 20190329052A1 · Kim et al. · 2019 [cited by applicant]
US 20220379120A1 · Prutchi et al. · 2022 [cited by applicant]
US 20220387790A1 · Prutchi et al. · 2022 [cited by applicant]
US 20230001204A1 · Prutchi et al. · 2023 [cited by applicant]
US 20230173280A1 · Prutchi et al. · 2023 [cited by applicant]
CA 2459408 · 2003 [cited by applicant]
CN 1787850 · 2006 [cited by applicant]
CN 1882296 · 2006 [cited by applicant]
CN 101827629 · 2010 [cited by applicant]
CN 104321107 · 2015 [cited by applicant]
CN 107261324 · 2017 [cited by applicant]
EP 0334675 · 1989 [cited by applicant]
EP 0600631 · 1994 [cited by applicant]
EP 0910429 · 1999 [cited by applicant]
EP 2659931 · 2013 [cited by applicant]
JP 2007503286 · 2007 [cited by applicant]
JP 2008532630 · 2008 [cited by applicant]
JP 2010104750 · 2010 [cited by applicant]
JP 2011502552 · 2011 [cited by applicant]
JP 2012502729 · 2012 [cited by applicant]
JP 2012504468 · 2012 [cited by applicant]
JP 2015503397 · 2015 [cited by applicant]
WO WO2004080533 · 2004 [cited by applicant]
WO WO2010039877 · 2010 [cited by applicant]
WO WO2021079316 · 2021 [cited by applicant]
WO WO2021079318 · 2021 [cited by applicant]
WO WO2021079319 · 2021 [cited by applicant]
WO WO2021198755 · 2021 [cited by applicant]
Official Action Dated Jan. 17, 2024 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/857,085. (11 pages). [cited by applicant]
International Preliminary Report on Patentability Dated May 5, 2022 From the International Bureau of WIPO Re. Application No. PCT/IB2020/059943. (8 Pages). [cited by applicant]
International Preliminary Report on Patentability Dated May 5, 2022 From the International Bureau of WIPO Re. Application No. PCT/IB2020/059947. (10 Pages). [cited by applicant]
International Preliminary Report on Patentability Dated May 5, 2022 From the International Bureau of WIPO Re. Application No. PCT/IB2020/059949. (10 Pages). [cited by applicant]
International Preliminary Report on Patentability Dated Jul. 21, 2022 From the International Preliminary Examining Authority Re. Application No. PCT/IB2020/059944. (21 Pages). [cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Dec. 22, 2023 From the European Patent Office Re. Application No. 20801017.3 (4 Pages). [cited by applicant]
International Search Report and the Written Opinion Dated Feb. 4, 2021 From the International Searching Authority Re. Application No. PCT/IB2020/059949. (14 Pages). [cited by applicant]
International Search Report and the Written Opinion Dated Aug. 12, 2021 From the International Searching Authority Re. Application No. PCT/IB2020/059947. (16 Pages). [cited by applicant]
International Search Report and the Written Opinion Dated Jan. 14, 2021 From the International Searching Authority Re. Application No. PCT/IB2020/059943. (17 Pages). [cited by applicant]
International Search Report and the Written Opinion Dated Aug. 20, 2021 From the International Searching Authority Re. Application No. PCT/IB2020/059944. (18 Pages). [cited by applicant]
Invitation to Pay Additional Fees, Communication Relating to the Result of the Partial International Search and the Provisional Opinion Dated Apr. 20, 2021 From the International Searching Authority Re. Application No. … [cited by applicant]
Invitation to Pay Additional Fees, Communication Relating to the Result of the Partial International Search and the Provisional Opinion Dated Apr. 26, 2021 From the International Searching Authority Re. Application No. … [cited by applicant]
Written Opinion Dated Mar. 15, 2022 From the International Searching Authority Re. Application No. PCT/IB2020/059944. (9 Pages). [cited by applicant]
Abi-Samra et al. “Cardiac Contractility Modulation: A Novel Approach for the Treatment of Heart Failure”, Heart Fail Reviews 21:645-660, Jul. 9, 2016. [cited by applicant]
Abraham et al. “A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation in Patients With Moderately Reduced Left Ventricular Ejection Fraction and A Narrow QRS Duration: Stu… [cited by applicant]
Abraham et al. “A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation”, Journal of the American College of Cardiology, JACC: Heart Failure, 6(10): 874-883, Published Onlin… [cited by applicant]
Abraham et al. “Subgroup Analysis of A Randomized Controlled Trial Evaluating the Safety and Efficacy of Cardiac Contractility Modulation in Advanced Heart Failure”, Journal of Cardiac Failure, 17(9): 710-717, Published… [cited by applicant]
Anker et al. “Cardiac Contractility Modulation Improves Long-Term Survival and Hospitalizations in Heart Failure With Reduced Ejection Fraction”, European Journal of Heart Failure, 21(9): 1103-1113, Published Online Jan… [cited by applicant]
Borggrefe et al. “Randomized, Double Blind Study of Non-Excitatory, Cardiac Contractility Modulation Electrical Impulses for Symptomatic Heart Failure”, European Heart Journal, 29(8): 1019-1028, Published Online Feb. 12… [cited by applicant]
Giallauria et al. “Effects of Cardiac Contractility Modulation by Non-Excitatory Electrical Simulation on Exercise Capacity and Quality of Life: An Individual Patient's Data Meta-Analysis of Randomized Controlled Trials… [cited by applicant]
Ibrahim et al. “Power Prior Distributions for Regression Models”, Statistical Science, 15(1): 46-60, Feb. 2000. [cited by applicant]
Kadish et al. “A Randomized Controlled Trial Evaluating the Safety and Efficacy of Cardiac Contractility Modulation in Advanced Heart Failure”, American Heart Journal, 161(2): 329-337, Feb. 2011. [cited by applicant]
Kuschyk et al. “Efficacy and Survival in Patients With Cardiac Contractility Modulation: Long-Term Single Center Experience in 81 Patients”, International Journal of Cardiology, 183: 76-81, Available Online Jan. 20, 201… [cited by applicant]
Liu et al. “Improvement of Long-Term Survival by Cardiac Contractility Modulation in Heart Failure Patients: A Case-Control Study”, International Journal of Cardiology, 206: 122-126, Available On line Jan. 6, 2016. [cited by applicant]
Lyon et al. “Cardiac Contractility Modulation Therapy in Advanced Systolic Heart Failure”, Nature Reviews Cardiology, XP0557621686, 10(10): 584-598, Advance Online Publication Aug. 13, 2013. [cited by applicant]
Mando et al. “Outcomes of Cardiac Contractility Modulation: A Systemic Review and Meta-Analysis of Randomized Clinical Trials”, Cardiovascular Therapeutics, 2019(Art.ID 9769724): 1-10, Jun. 17, 2019. [cited by applicant]
Mueller et al. “Clinical Effects of Long-Term Cardiac Contractility Modulation (CCM) in Subjects With Heart Failure Caused by Left Ventricular Systolic Dysfunction”, Clinical Research of Cardiology, 106(11): 893-904, Pu… [cited by applicant]
Neelagaru et al. “Nonexcitatory, Cardiac Contractility Modulation Electrical Impulses: Feasibility Study for Advanced Heart Failure in Patients With Normal QRS Duration”, Heart Rythm, 3(10): 1140-1147, Published Online … [cited by applicant]
Schoene ct al. “Cardiac Contractility Modulation Provides Improved Ventilatory Efficiency and Reduces Oscillatory Breathing Pattern”, European Heart Journal, Poster Session 4: Advanced Heart Failure, 40(Suppl.1): 2133: … [cited by applicant]
Schuirmann “Pharmacometrics: A Comparison of the Two One-Sided Tests Procedure and the Power Approach for Assessing the Equivalence of Average Bioavailability”, Journal of Pharmacokinetics and Biopharmaceutics, 15(6): 6… [cited by applicant]
Tint et al. “New Generation Cardiac Contractility Modulation Device—Filling the Gap in Heart Failure Treatment”, Journal of Clinical Medicine, 8(5): 588-1-588-10, Apr. 29, 2019. [cited by applicant]
Tschoepe et al. “Cardiac Contractility Modulation: Mechanisms of Action in Heart Failure with Reduced Ejection Fraction and Beyond”, European Journal of Heart Failure, 21(1):14-20, Nov. 28, 2018. [cited by applicant]
Uskach et al. “Possibilities and Perspectives of Using Cardiac Contractility Modulation in Patients With Chronic Heart Failure and Atrial Fibrillation”, Kardiologiia, 59(2S): 4-14, 2019 & English Abstract. [cited by applicant]
Wang et al. “Meta-Analysis of the Incidence of Lead Dislodgement With Conventional and Leadless Pacemaker Systems”, Pacing and Clinical Electrophysiology, PACE, 41(10): 1365-1371, Published Online Aug. 27, 2018. [cited by applicant]
Yu et al. “Impact of Cardiac Contractility Modulation on Left Ventricular Global and Regional Function and Remodeling”, Journal of the American College of Cardiology, JACC: Cardiovascular Imaging, 2(12): 1341-1349, Dec.… [cited by applicant]
Official Action Dated Sep. 8, 2023 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/857,085. (24 pages). [cited by applicant]
Eisman et al. “Pulmonary Capillary Wedge Pressure Patterns During Exercice Predict Exercise Capacity and Incident Heart Failure”, Circulation: Heart Failure, 11(5): 1-9, May 2018. [cited by applicant]
Meluzin et al. “Improvement in The Prediction of Exercise-Induced Elevation of Left Ventricular Filling Pressure in Patients With Normal Left Ventricular Ejection Fraction”, Echocardiography, 34(1): 78-86, Oct. 25, 2016… [cited by applicant]
Official Action Dated Aug. 5, 2024 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/857,085. (21 pages). [cited by applicant]
Cleveland Clinic “Hypertrophic Cardiomyopathy”, Cleveland Clinic, Retrieved Online, pp. 1-2, 2021. [cited by applicant]
Meluzin et al. “Noninvasive Prediction of the Exercise-Induced Elevation in Left Ventricular Filling Pressure in Post-Heart Transplant Patients With Normal Left Ventricular Ejection Fraction”, Clinical Cardiology, 18(2)… [cited by applicant]
Notice of Reason(s) for Rejection Dated Jun. 11, 2024 From the Japan Patent Office Re. Application No. 2022-523998 and Its Translation Into English. (10 Pages). [cited by applicant]
Notice of Reason(s) for Rejection Dated Jun. 6, 2024 From the Japan Patent Office Re. Application No. 2022-523513 and Its Translation Into English. (12 Pages). [cited by applicant]
Notice of Reason(s) for Rejection Dated May 28, 2024 From the Japan Patent Office Re. Application No. 2022-523514 and Its Translation Into English. (14 Pages). [cited by applicant]
Additional Search Fees Due under Rule 164(2)(a) EPC Dated Feb. 26, 2025 From the European Patent Office Re. Application No. 20803263.1 (5 pages). [cited by applicant]
Notice of Reason(s) for Rejection Dated Mar. 4, 2025 From the Japan Patent Office Re. Application No. 2022-523514 and Its Translation Into English. (12 Pages). [cited by applicant]
Notice of Reason(s) for Rejection Dated Feb. 12, 2025 From the Japan Patent Office Re. Application No. 2022-523998 and Its Translation Into English. (9 Pages). [cited by applicant]
Notification of Office Action and Search Report Dated Apr. 1, 2025 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 202080089348.6 and Its Machine Translation of Office A… [cited by applicant]
Notification of Office Action and Search Report Dated Mar. 19, 2025 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 202080088570.4 and its Translation of the Office Acti… [cited by applicant]
Notification of Office Action and Search report Dated Mar. 21, 2025 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 202080090192.3 and Its Translation in English (18 Pag… [cited by applicant]
Notification of Office Action and Search Report Dated Mar. 26, 2025 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 202080101268.8 and Its Machine Translation of Office … [cited by applicant]
Official Action Dated Feb. 6, 2025 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/911,676. (48 pages). [cited by applicant]
Oliver et al. “Anatomy, Thorax, Phrenic Nerves”, Europe PMC, Search life-sciences literature, Study Guide from StatPearls Publishing, Treasure Island (FL), PMID: 30020697, Jul. 19, 2018. dowloaded from https://europepmc… [cited by applicant]
Pre Appeal Examination Dated Aug. 18, 2025 From the Japan Patent Office Re. Application No. 2022-523514 and Its Translation Into English. (4 Pages). [cited by applicant]
Interview Summary Dated Nov. 12, 2024 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/857,085. (8 pages). [cited by applicant]
Notice of Reasons for Rejection Dated Dec. 3, 2024 From the Japan Patent Office Re. Application No. 2022-523513 and Its Translation into English. (10 Pages). [cited by applicant]
Restriction Official Action Dated Dec. 30, 2024 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/770,318. (5 pages). [cited by applicant]
Restriction Official Action Dated Jan. 6, 2025 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/770,707. (12 pages). [cited by applicant]